Diabetic cardiomyopathy: how much does it depend on AGE? - PubMed (original) (raw)

Diabetic cardiomyopathy: how much does it depend on AGE?

M Montagnani. Br J Pharmacol. 2008 Jun.

Abstract

Diabetic cardiomyopathy refers to dysfunction of cardiac muscle in patients with diabetes that cannot be directly ascribed to hypertension, coronary heart disease or other defined cardiac abnormalities per se. The development of diabetic cardiomyopathy may involve several distinct mechanisms, including increased formation of advanced glycation end products (AGEs) secondary to hyperglycaemia. AGEs may alter structural proteins and lead to increased arterial and myocardial stiffness. Therefore, therapies that prevent or retard development of AGEs in diabetes may be valuable strategies to treat or prevent diabetic cardiomyopathy. In this issue of British Journal of Pharmacology, Wu and colleagues demonstrate that aminoguanidine (inhibitor of AGE formation and protein cross-linking) treatment of a rat model of type I diabetes (rats made insulin deficient with streptozotocin and nicotinamide treatment) ameliorates detrimental changes in left ventricular structure and function. Results from this study are in agreement with previous investigations, suggesting that aminoguanidine is effective in preventing cardiac hypertrophy and arterial stiffening in experimental animal models of diabetes and emphasize the potential pathogenic role of AGEs in diabetic cardiomyopathy.

PubMed Disclaimer

Similar articles

• Inhibition of Advanced Glycation End Products Formation Attenuates Cardiac Electrical and Mechanical Remodeling and Vulnerability to Tachyarrhythmias in Diabetic Rats.
  Chang GJ, Yeh YH, Chen WJ, Ko YS, Pang JS, Lee HY. Chang GJ, et al. J Pharmacol Exp Ther. 2019 Jan;368(1):66-78. doi: 10.1124/jpet.118.252080. Epub 2018 Oct 31. J Pharmacol Exp Ther. 2019. PMID: 30381326
• Aminoguanidine prevents the impairment of cardiac pumping mechanics in rats with streptozotocin and nicotinamide-induced type 2 diabetes.
  Wu MS, Liang JT, Lin YD, Wu ET, Tseng YZ, Chang KC. Wu MS, et al. Br J Pharmacol. 2008 Jun;154(4):758-64. doi: 10.1038/bjp.2008.119. Epub 2008 Mar 31. Br J Pharmacol. 2008. PMID: 18376420 Free PMC article.
• Inhibition of advanced glycation endproduct (AGE) rescues against streptozotocin-induced diabetic cardiomyopathy: Role of autophagy and ER stress.
  Pei Z, Deng Q, Babcock SA, He EY, Ren J, Zhang Y. Pei Z, et al. Toxicol Lett. 2018 Mar 1;284:10-20. doi: 10.1016/j.toxlet.2017.11.018. Epub 2017 Nov 22. Toxicol Lett. 2018. PMID: 29174818
• Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes.
  Aronson D. Aronson D. J Hypertens. 2003 Jan;21(1):3-12. doi: 10.1097/00004872-200301000-00002. J Hypertens. 2003. PMID: 12544424 Review.
• Diabetic cardiomyopathy revisited.
  Boudina S, Abel ED. Boudina S, et al. Circulation. 2007 Jun 26;115(25):3213-23. doi: 10.1161/CIRCULATIONAHA.106.679597. Circulation. 2007. PMID: 17592090 Review.

Cited by

• Molecular mechanisms of metabolic dysregulation in diabetic cardiomyopathy.
  Zeng Y, Li Y, Jiang W, Hou N. Zeng Y, et al. Front Cardiovasc Med. 2024 Mar 25;11:1375400. doi: 10.3389/fcvm.2024.1375400. eCollection 2024. Front Cardiovasc Med. 2024. PMID: 38596692 Free PMC article. Review.
• The Intrinsic Virtues of EGCG, an Extremely Good Cell Guardian, on Prevention and Treatment of Diabesity Complications.
  Potenza MA, Iacobazzi D, Sgarra L, Montagnani M. Potenza MA, et al. Molecules. 2020 Jul 4;25(13):3061. doi: 10.3390/molecules25133061. Molecules. 2020. PMID: 32635492 Free PMC article. Review.
• LCZ696 Protects against Diabetic Cardiomyopathy-Induced Myocardial Inflammation, ER Stress, and Apoptosis through Inhibiting AGEs/NF-κB and PERK/CHOP Signaling Pathways.
  Belali OM, Ahmed MM, Mohany M, Belali TM, Alotaibi MM, Al-Hoshani A, Al-Rejaie SS. Belali OM, et al. Int J Mol Sci. 2022 Jan 24;23(3):1288. doi: 10.3390/ijms23031288. Int J Mol Sci. 2022. PMID: 35163209 Free PMC article.
• Diabetic cardiomyopathy--to take a long story serious.
  Stratmann B, Gawlowski T, Tschoepe D. Stratmann B, et al. Herz. 2010 May;35(3):161-8. doi: 10.1007/s00059-010-3336-0. Herz. 2010. PMID: 20467928
• Molecular and clinical aspects of endothelial dysfunction in diabetes.
  Nacci C, Tarquinio M, Montagnani M. Nacci C, et al. Intern Emerg Med. 2009 Apr;4(2):107-16. doi: 10.1007/s11739-009-0234-7. Epub 2009 Mar 10. Intern Emerg Med. 2009. PMID: 19280353

References

1. 1. Avendano GF, Agarwal RK, Bashey RI, Lyons MM, Soni BJ, Jyothirmayi GN, et al. Effects of glucose intolerance on myocardial function and collagen-linked glycation. Diabetes. 1999;48:1443–1447. - PubMed
2. 1. Bolton WK, Cattran DC, Williams ME, Adler SG, Appel GB, Cartwright K, et al. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol. 2004;24:32–40. - PubMed
3. 1. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med. 1988;318:1315–1321. - PubMed
4. 1. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science. 1986;232:1629–1632. - PubMed
5. 1. Chang KC, Tseng CD, Wu MS, Liang JT, Tsai MS, Cho YL, et al. Aminoguanidine prevents arterial stiffening in a new rat model of type 2 diabetes. Eur J Clin Invest. 2006;36:528–535. - PubMed

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • Ovid Technologies, Inc.
  • PubMed Central
  • Wiley

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Consumer Health Information
  • MedlinePlus Health Information